NCIt definition : An orally bioavailable selective MEK inhibitor with potential antineoplastic activity.
Refametinib specifically inhibits mitogen-activated protein kinase kinase 1 (MAP2K1
or MAPK/ERK kinase 1), resulting in inhibition of growth factor-mediated cell signaling
and tumor cell proliferation. MEK, a dual specificity threonine/tyrosine kinase, is
a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth;
constitutive activation of this pathway has been implicated in many cancers.;
UNII : JPX07AFM0N;
InChIKey : RDSACQWTXKSHJT-NSHDSACASA-N;
CAS number : 923032-37-5; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 923032-37-5
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Currated CISMeF NLP mapping